Dow Up1.31% Nasdaq Up2.40%

United Therapeutics Corporation (UTHR)

-NasdaqGS
127.61 1.15(0.91%) Oct 21, 4:00PM EDT
ProfileGet Profile for:
United Therapeutics Corporation
1040 Spring Street
Silver Spring, MD 20910
United States - Map
Phone: 301-608-9292
Fax: 301-608-9291
Website: http://www.unither.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:706

Business Summary 

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on United Therapeutics Corporation

Corporate Governance 
United Therapeutics Corporation’s ISS Governance QuickScore as of Oct 1, 2014 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 10; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Dr. Martine A. Rothblatt Ph.D., J.D., MBA, 59
Founder, Chairman and Chief Exec. Officer
2.12M4.65M
Dr. Roger A. Jeffs Ph.D., 52
Pres, Chief Operating Officer and Director
1.50M0.00
Mr. John M. Ferrari , 59
Chief Financial Officer, Principal Accounting Officer and Treasurer
918.00K0.00
Mr. Paul A. Mahon J.D., 50
Exec. VP of Strategic Planning, Gen. Counsel and Corp. Sec.
1.19M5.38M
Dr. Martin D. Auster M.D.,
VP of Bus. Devel.
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders